European Medicines Agency recommends granting a conditional marketing authorisation for vismodegib

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product vismodegib (Erivedge) 150 mg, hard capsule, intended for the treatment of adult patients with symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy. Read more here.